SABCS 2011: Dual HER2 Blockade Significantly Extends Progression-Free Survival
December 8, 2011
Results of the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) trial will be presented today at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium and are also published in the New England Journal of Medicine. These findings suggest that the combination of two HER2 blocking agents, trastuzumab and pertuzumab, when used with docetaxel, prolongs progression-free survival compared to treatment with trastuzumab and docetaxel alone. In the CLEOPATRA trial, researchers randomly assigned 808 patients with HER2-positive metastatic breast cancer to receive placebo plus trastuzumab plus docetaxel (control group) or pertuzumab plus trastuzumab plus docetaxel (pertuzumab group) as first-line treatment until the time of disease progression or the development of unmanagable toxic effects. The median (independently assessed) progression-free survival was prolonged by 6.1 months with the addition of pertuzumab, from 12.4 months in the control group to 18.5 months in the pertuzumab group. The objective response rate, measured by tumor shrinkage of at least 30%, was 69.3% in the control group, as compared with 80.2% in the pertuzumab group. No additional cardiac toxicity was observed in the pertuzumab group. It is too early for an overall survival analysis, which is estimated to be performed in late 2013.
According to first author José Baselga, M.D., Ph.D. of Harvard Medical School, "Most metastatic patients with HER2-positive breast cancer eventually stop responding to trastuzumab, so the fact that we now have an agent that can be added to current treatment to delay progression is very exciting."
MYTHS VS. TRUTHS
Brush up on your breast cancer myths and truths. Find out if you know more about breast cancer than the American public.
I'll Talk
Speak up and out about breast cancer. Say, "I'll Talk" and commit to a conversation about breast cancer with people you know and care about.
Understanding Research and Evidence
Comments
Tina
Date: May 7, 2012ZHT
Date: May 14, 2012Nike tn
Date: May 15, 2012Nike Basketball took some time out of Nike Tn the day to officially Tn Requin unveil their 2012 NBA All-Star Game Collection and it Nike Tn looks great. The shoes Tn Pas Cher drop includes three Coach Outlet Online silhouettes that are given a bit of Nike TN Tn Pas Cher an intergalactic spark thanks to an Air & Space theme that is complete with a glow in Tn Requin the dark outsole.Coach Outlet Included in the drop are the Coach Outlet Store Online Nike Zoom KD 4, Nike LeBron 9 and Nike Nike tn requin Zoom Kobe 7 and each one features a very solid colorway with a Tn Pas Cher vibrant outsole.
You have seen a few Five Finger Shoes posts about the Vibram five finger new Vibram FiveFingers Speed colorways Vibram FiveFingers that have been released this Vibram FiveFingers month. I was quite fond of Five Finger Shoes the Orange and Green Vibram five finger pair as well as the Brown and Tan pair. Once I saw Vibram Five Fingers that they were available at TravelCountry, Vibram Shoes I jumped on the chance to Vibram 5 Fingers pick up both of them.
Hermes’ street style shots with Hermes Replica Bag actual accessories attached Hemes Bracelet to them in the windows offers a very Hermes Bag refreshing concept. I’ve liked Hermes Birkin Bag street style fashion photography Hermes Replica Bag ever since university; it was Hermes Belt our way of finding out new directions in fashion, Hermes Bag and a lot of companies use Hermes Birkin Bag this technique to make their Coach Factory Outlet fashion seem like it’s emerging from the streets.
Nike Requin
Date: May 16, 2012